Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

ACC, SCAI, HRS release consensus statement on left atrial appendage occlusion requirements

Three leading cardiology societies released a consensus statement on Dec. 10 regarding criteria institutions and operators should follow for left atrial appendage occlusion.

FDA investigates reports of reduced leaflet motion in bioprosthetic aortic valves

After receiving reports regarding reduced leaflet motion in some bioprosthetic aortic valves, the FDA announced on Oct. 5 that the agency is working with the American College of Cardiology, the Society of Thoracic Surgeons and device manufacturers to design clinical studies to evaluate the situation.

Medtronic agrees to acquire privately-held TMVR device manufacturer

Medtronic agreed to acquire Twelve, a private medical device company that is developing a transcatheter mitral valve replacement (TMVR) device. The $458 million transaction is expected to close in October, according to a Medtronic news release.

Medtronic recalls EnVeo R loading systems

Medtronic recalled 6,912 units of the EnVeo R loading systems after receiving two reports of particulates in packaged kits and six reports of particulates in the loading bath during valve loading as of July 6.

Abbott commits to mitral valve disease treatments with two transactions

With two transactions on July 30, Abbott strengthened its structural heart business and emphasized its focus on treatments for mitral valve disease.

Thumbnail

After 2 years, low stroke rates in TAVR patients

Fewer than six percent of patients who underwent transcatheter aortic valve replacement (TAVR) with the CoreValve device had strokes within two years of the procedure, according to a recent study. Researchers mentioned the 5.6 percent overall stroke rate was relatively low considering all patients were high-risk and had symptomatic aortic stenosis.

Thumbnail

The Lowdown on TAVR: As Risk Drops, Expectations Rise

The prevailing wisdom is that transcatheter aortic valve replacement (TAVR) will waltz into the intermediate-risk category and then skip over to low-risk patients with severe aortic stenosis. 

Thumbnail

TAVR’s Traditions & Transitions

Transcatheter aortic valve replacement (TAVR) has progressed at lightning speed. Some cardiologists now debate what may be getting lost amid this rapid change.

Displaying 1113 - 1120 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.